Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Director David P. Hochman bought 5,000 shares of the stock in a transaction that occurred on Wednesday, March 14th. The shares were purchased at an average price of $6.67 per share, with a total value of $33,350.00. Following the completion of the acquisition, the director now directly owns 459,500 shares in the company, valued at $3,064,865. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
NASDAQ:CRBP traded down $0.15 during mid-day trading on Friday, reaching $5.65. 395,839 shares of the stock were exchanged, compared to its average volume of 674,985. Corbus Pharmaceuticals Holdings Inc has a 1 year low of $5.30 and a 1 year high of $9.95. The company has a market capitalization of $322.81, a PE ratio of -8.69 and a beta of 2.23.
Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 75.88%. equities research analysts predict that Corbus Pharmaceuticals Holdings Inc will post -0.81 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in CRBP. State Board of Administration of Florida Retirement System purchased a new position in shares of Corbus Pharmaceuticals in the 3rd quarter valued at approximately $108,000. Yellowstone Partners LLC purchased a new stake in shares of Corbus Pharmaceuticals in the third quarter valued at approximately $110,000. Voya Investment Management LLC purchased a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at approximately $125,000. Aries Wealth Management purchased a new stake in shares of Corbus Pharmaceuticals in the fourth quarter valued at approximately $153,000. Finally, Nationwide Fund Advisors purchased a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at approximately $158,000. Institutional investors own 37.01% of the company’s stock.
A number of equities research analysts have issued reports on CRBP shares. Cantor Fitzgerald set a $28.00 price target on Corbus Pharmaceuticals and gave the company an “overweight” rating in a research report on Thursday, December 14th. Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals in a research report on Friday, December 15th. BidaskClub lowered Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. Raymond James Financial started coverage on Corbus Pharmaceuticals in a research report on Friday, January 19th. They set an “outperform” rating and a $24.00 target price on the stock. Finally, ValuEngine raised Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $25.33.
ILLEGAL ACTIVITY NOTICE: “Insider Buying: Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Director Acquires 5,000 Shares of Stock” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/09/david-p-hochman-buys-5000-shares-of-corbus-pharmaceuticals-holdings-inc-crbp-stock.html.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.